Descripción de la empresa
Collegium Pharmaceutical, Inc. operates within the healthcare sector, specifically as a manufacturer of specialty and generic drugs, with a primary focus on the development and commercialization of medicines designed for pain management. The company's portfolio features notable assets such as Jornay PM, a central nervous system stimulant prescription medicine containing methylphenidate HCl intended for treatment purposes. In terms of scale, the enterprise maintains a market capitalization of $1.04 billion, generates annual revenue of $780.57 million, and employs a workforce of 423 individuals. These financial dimensions indicate that Collegium occupies a mid-sized position within the pharmaceutical landscape, possessing sufficient capitalization to support specialized R&D initiatives while maintaining a revenue base that places it among the larger specialty drug manufacturers, though its employee count suggests a lean, highly specialized operational model rather than mass-market distribution capabilities.
Salud financiera
The company reported trailing twelve-month revenue of $780.57 million and net income of $62.87 million, resulting in an EBITDA of $419.16 million. The substantial gap between revenue and net income reveals a significant cost structure comprising operating expenses, taxes, and other deductions that reduce the bottom line by approximately 91.9% of total sales. Free cash flow stands at $321.54 million, which signifies a robust generation of cash from operations after capital expenditures, providing the firm with considerable financial flexibility to fund future growth, repay obligations, or pursue strategic acquisitions without immediate external financing. The gross margin is reported at 88.5%, indicating high pricing power or low cost of goods sold typical of patented specialty drugs; the operating margin sits at 30.0%, reflecting efficient management of administrative and selling expenses; and the profit margin is 8.1%, showing the final profitability after all costs including interest and taxes. Regarding balance sheet leverage, total cash reserves amount to $386.68 million while total debt reaches $936.43 million, creating a net debt position that implies a leveraged balance sheet rather than a conservative one, a stance further highlighted by a debt-to-equity ratio of 310.41. Despite the debt load, the current ratio is 1.57, which indicates a comfortable level of short-term liquidity where current assets exceed current liabilities by a healthy margin. Return on equity is 23.7% and return on assets is 7.3%, metrics that reveal highly effective management in utilizing shareholder equity to generate returns, while the ROA suggests a moderate efficiency in deploying the total asset base to produce earnings.
Evaluación de valoración
The stock trades with a trailing P/E ratio of 18.83 and a forward P/E of 5.13. The significant disparity between these two metrics implies that the market expects earnings to grow substantially in the coming year, as the forward multiple is less than one-third of the trailing multiple. The price-to-book ratio is 3.44, indicating that the market values the company at a substantial premium over its net asset value, reflecting confidence in its intangible assets, patent portfolio, and future cash flow generation. Alternative valuation metrics such as the price-to-sales ratio of 1.33 and an EV/EBITDA of 3.79 suggest the stock is priced reasonably relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization, particularly when considering the high growth expectations embedded in the forward P/E. The stock's price has fluctuated between a 52-week high of $50.79 and a 52-week low of $23.23, meaning the current share price sits significantly below the yearly peak but well above the yearly trough. The beta value is 0.77, which means the stock exhibits lower volatility relative to the broader market, moving less dramatically than the overall index during periods of market turbulence.
Growth & Income
Revenue growth year-over-year stands at 12.9%, while earnings growth year-over-year is 31.5%, indicating that earnings are expanding at a rate more than double that of revenue. This divergence implies that the company is benefiting from margin expansion, likely driven by cost efficiencies, pricing power, or the commercialization of high-value assets like Jornay PM. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to reinvest into research, development, and market expansion rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by aggressive capital retention to fuel internal growth initiatives, supported by a balance sheet that generates substantial free cash flow despite the existing debt obligations.